Endothelial progenitor cell therapy for the treatment of coronary disease, acute MI, and pulmonary arterial hypertension: current perspectives.
Since their identification in 1997, bone marrow derived endothelial progenitor cells (EPCs) have been studied for their role in the endogenous maintenance and repair of endothelium and their potential regenerative capacity beyond the endothelium. In particular, EPCs have been tested in cell therapy approaches with the aim of developing novel therapies for conditions currently lacking effective treatment options. In this review, we discuss the scientific background and clinical experience using EPC delivery or mobilization for the treatment of post-angioplasty restenosis, acute myocardial infarction and pulmonary arterial hypertension. Although these approaches are safe, efficacy has yet to be proven in large randomized clinical trials. Unfortunately, the biology of EPCs is still poorly understood. The success of future clinical trials depends on a better understanding of EPC biology and intelligent design.
Division of Cardiology, St. Michael's Hospital, Toronto, Ontario, Canada.
Michael R
MR
Ward
Duncan J
DJ
Stewart
Michael J B
MJ
Kutryk
D042501:Angiogenic Proteins / Q000235:genetics / Q000378:metabolism*; D000818:Animals; D003327:Coronary Disease / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery*; D023903:Coronary Restenosis / Q000378:metabolism / Q000601:surgery; D004195:Disease Models, Animal; D042783:Endothelial Cells / Q000378:metabolism / Q000637:transplantation*; D015316:Genetic Therapy / Q000379:methods*; D006801:Humans; D006976:Hypertension, Pulmonary / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery*; D009203:Myocardial Infarction / Q000235:genetics / Q000378:metabolism / Q000503:physiopathology / Q000601:surgery*; D018919:Neovascularization, Physiologic; D033581:Stem Cell Transplantation; D023822:Tissue Engineering / Q000379:methods*; D016896:Treatment Outcome
D042501:Angiogenic Proteins